Amylin Pharmaceuticals Reports Second Quarter Financi...(798 $54789 $99546 $114550 ...),Health

Date:7/21/2009

,798 $54,789 $99,546 $114,550 ======= ======= ======= ======== AMYLIN PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) June 30, December 31, 2009 2008 ---- ---- Assets Cash, cash equivalents and short-term investments $644,438 $816,838 Accounts receivable, net 76,405 62,369 Inventories, net 109,803 115,823 Other current assets 64,839 41,038 Property and equipment, net 714,541 655,444 Other assets 40,341 35,541 ---------- ---------- Total assets $1,650,367 $1,727,053 ========== ========== Liabilities and stockholders' equity Current liabilities 279,484 313,778 Other liabilities, net of current portion 191,002 179,227 Long-term debt 710,255 714,771 Stockholders' equity 469,626 519,277 ---------- ---------- Total liabilities and stockholders' equity $1,650,367 $1,727,053 ========== ==========

'/>"/>

SOURCE Amylin Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Lilly and Amylin Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
11. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission